Shots:

• The P-II Spotlight 203 study will evaluate the combination of BO-112 (intra-tumoral administration) + Keytruda (pembrolizumab) with CR or PR as its 1EPs. The study will evaluate disease control rates- DoR- PFS- OS- as well as safety- tolerability- and PK of the therapy in ~40 patients
• The collaboration will focus on the evaluation of the combination therapy in patients that have progressed on anti-PD-1-based therapy in refractory advanced MM
• The P-II study of combination therapy in patients with liver metastases from colorectal or gastric/GEJ cancer is currently under progress. Highlight Therapeutics has been dosed it first patient P-IIa study in liver metastasis

­ Ref: PRNewswire | Image: Merck